• 검색어에 아래의 연산자를 사용하시면 더 정확한 검색결과를 얻을 수 있습니다.
  • 검색연산자
검색연산자 기능 검색시 예
() 우선순위가 가장 높은 연산자 예1) (나노 (기계 | machine))
공백 두 개의 검색어(식)을 모두 포함하고 있는 문서 검색 예1) (나노 기계)
예2) 나노 장영실
| 두 개의 검색어(식) 중 하나 이상 포함하고 있는 문서 검색 예1) (줄기세포 | 면역)
예2) 줄기세포 | 장영실
! NOT 이후에 있는 검색어가 포함된 문서는 제외 예1) (황금 !백금)
예2) !image
* 검색어의 *란에 0개 이상의 임의의 문자가 포함된 문서 검색 예) semi*
"" 따옴표 내의 구문과 완전히 일치하는 문서만 검색 예) "Transform and Quantization"

특허 상세정보

Na/K-ATPase ligands, ouabain antagonists, assays and uses thereof

국가/구분 United States(US) Patent 등록
국제특허분류(IPC7판) A61K-031/353    A61K-031/35    A61K-031/352   
출원번호 US-0045269 (2013-10-03)
등록번호 US-9114126 (2015-08-25)
발명자 / 주소
출원인 / 주소
대리인 / 주소
    MacMillan, Sobanski & Todd, LLC
인용정보 피인용 횟수 : 0  인용 특허 : 17

The present disclosure relates to methods of inhibiting the ATPase activity of Na/K-ATPase without stimulating the receptor function, methods of blocking Na/K-ATPase interaction with Src, methods of inhibiting cell growth, and methods of abolishing ouabain-provoked signaling transduction in the heart of a subject, which includes providing an effective amount of at least one hydroxyl xanthone derivative.


1. A method for inhibiting cancer cell proliferation comprising: administering to a subject in need thereof an effective amount of at least one Na/K-ATPase ligand selected from the group consisting of: MB5 (3,4,5-trihydroxyxanthone) and MB7 (3,4,5,6-tetrahydroxyxanthone);andinhibiting the ATPase activity without stimulating the receptor function of Na/K-ATPase in the subject in need of inhibition of cancer cell proliferation. 2. The method of claim 1, wherein the Na/K-ATPase ligand is MB5 (3,4,5-trihydroxyxanthone). 3. The method of claim 1, wherein the ...

이 특허에 인용된 특허 (17)

  1. Larson, Drake. Catechin multimers as therapeutic drug delivery agents. USP2003056562864.
  2. Waller Todd A.. Cinnamoyl-C-glycoside chromone isolated from aloe barbadensis. USP1999105965540.
  3. Maroko Peter R. (1765 Garwood Dr. Cherry Hill NJ 08003). Compositions and method of treatment for improving circulatory performance. USP1992105153178.
  4. Singh, Chandra Ulagaraj; Nulu, Jagaveerabhadra Rao. Derivatives of sandalwood oil and santalols for treating cold sores and herpes. USP2010127858126.
  5. Nashimoto Kazuo,JPX ; Tashiro Yoshikazu,JPX. Gargling cup, antiviral mask, antiviral filter, antifungal, antibacterial, and antiviral filter air cleaner and air-clea. USP1999035888527.
  6. Shan,Jacqueline J.; Wu,Xi Chen; Pang,Peter K. T.; Ling,Lei. Hypericin andextract: specific T-type calcium channel blocker, and their use as T-type calcium channel targeted therapeutics. USP2007037195783.
  7. Zhao,Jian; Zhou,Rui; Chen,Hu. Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof. USP2007017157493.
  8. Xie, Zijian; Shapiro, Joseph I.; Tian, Jiang. Na+K+-ATPase-specific peptide inhibitors/activators of SRC and SRC family kinases. USP2012108283441.
  9. Ji, Joon Whan; Kang, Jae Ku; Kim, Young Hoon; Jung, Sung Hak; Cho, Hee Jae; Lee, Kwang Hyuk. Pharmaceutical composition for preventing and treating erectile impotence using purified sumsoo extract. USP2004046726935.
  10. Appelgren Curt H. (V Frlunda SEX) Bogentoft Conny B. (Kallered SEX). Pharmaceutically preparation comprising a cardiac glycoside in combination with a polymer. USP1981044261971.
  11. Smothers, Donald L.. Plant extraction method and compositions. USP2013098524286.
  12. Goodsall Christopher William,GBX ; Parry Andrew David,GBX ; Safford Richard,GBX ; Thiru Ambalavanar,GBX. Producing theaflavin. USP2000096113965.
  13. Fielding Christopher J. ; Fielding Phoebe E.. Regulation of the cell cycle by sterols. USP2001076261760.
  14. Addington, Otis Crandell; Zhang, Feng; Koleng, John J.. SCF extract containing cardiac glycoside. USP2013038394434.
  15. Burrell,Robert E.; Wright,John B.; Lam,Kan; Yin,Hua Qing; Naylor,Antony G.; Moxham,Peter H.; Gillis,Scott H.; Schechter,Paul. Solutions and aerosols of metal-containing compounds. USP2006077078060.
  16. Addington,Crandell. Supercritical carbon dioxide extract of pharmacologically active components from. USP2008077402325.
  17. Florkiewicz Robert Z.. Treatment of FGF-mediated conditions by administration of a cardiac glycoside or aglycone derivative thereof. USP2000066071885.